Data from brentuximab vedotin and dacetuzumab programs to be presented by Seattle Genetics

Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that data from its brentuximab vedotin (SGN-35) and dacetuzumab (SGN-40) programs will be reported at the upcoming 51^st American Society of Hematology (ASH) 2009 Meeting and Exposition being held December 5-8, 2009 in New Orleans, Louisiana. A summary of the company’s ASH presentations is below and full abstracts can be accessed at the ASH website at www.hematology.org.

Brentuximab vedotin data:

The antibody-drug conjugate brentuximab vedotin (SGN-35) induced multiple objective responses in patients with relapsed or refractory CD30-positive lymphomas in a phase 1 weekly dosing study

• Sunday, December 6, 2009, 6:00 p.m. - 8:00 p.m. Central Time (CT)
• Abstract # 2731 (poster board # II-707)
• First author: Dr. Michelle Fanale, MD Anderson Cancer Center, University of Texas, Houston, Texas

Dacetuzumab data:

Dacetuzumab (SGN-40), lenalidomide, and weekly dexamethasone in relapsed or refractory multiple myeloma: multiple responses observed in a phase 1b study

• Sunday, December 6, 2009, 6:00 p.m. - 8:00 p.m. CT
• Abstract # 2870 (poster board # II-846)
• First author: Dr. Edward Agura, Baylor Sammons Cancer Center, Dallas, Texas

CD40 pathway activation status predicts response to CD40 targeted therapy in diffuse large B-cell lymphoma

• Sunday, December 6, 2009, 6:00 p.m. - 8:00 p.m. CT
• Abstract # 2721 (poster board # II-697)
• First author: David Dornan, Ph.D., Genentech, Inc.

A phase 1b clinical trial of dacetuzumab in combination with rituximab and gemcitabine: multiple responses observed in patients with relapsed diffuse large B-cell lymphoma

• Monday, December 7, 2009, 3:30 p.m. CT
• Abstract # 586
• Oral presentation in rooms R02-R05
• First author: Dr. Andres Forero-Torres, Comprehensive Cancer Center, University of Alabama at Birmingham